{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:31:33Z","timestamp":1782887493345,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1007\/s10557-004-6225-z","type":"journal-article","created":{"date-parts":[[2005,3,15]],"date-time":"2005-03-15T14:22:23Z","timestamp":1110896543000},"page":"475-481","source":"Crossref","is-referenced-by-count":72,"title":["Self-Reported Adherence to Cholesterol-Lowering Medication in Patients with Familial Hypercholesterolaemia: The Role of Illness Perceptions"],"prefix":"10.1007","volume":"18","author":[{"given":"Victoria","family":"Senior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa M.","family":"Marteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Weinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Genetic Risk Assessment for FH Trial (GRAFT) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. NEJM 1995;333:1301?1307.","journal-title":"NEJM"},{"key":"CR2","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4s). Lancet 1994;344:1383?1389.","journal-title":"Lancet"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2796.1997.112133000.x","volume":"241","author":"W. Insull","year":"1997","unstructured":"Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317?325.","journal-title":"J Intern Med"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archinte.163.1.65","volume":"163","author":"MAW Umans-Eckenhausen","year":"2003","unstructured":"Umans-Eckenhausen MAW, Defesche JC, van Dam MJ, Kastelelein JJP. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Int Med 2003;163:65?68.","journal-title":"Arch Int Med"},{"key":"CR5","volume-title":"Adherence to Treatment in Medical Conditions","year":"1998","unstructured":"Myers LB, Midence K, eds. Adherence to Treatment in Medical Conditions. London: Harwood Academic Publishers, 1998."},{"key":"CR6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1998.00294.x","volume":"243","author":"M Erikson","year":"1998","unstructured":"Erikson M, Hadell K, Holme I, et al. Compliance with and efficacy of treatment with pravastatin and cholestyramine: A randomised study of lipid-lowering in primary care. J Intern Med 1998;243:373?380.","journal-title":"J Intern Med"},{"key":"CR7","doi-asserted-by":"crossref","unstructured":"Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: A cross-national study. JAMA 279:1458?1462.","DOI":"10.1001\/jama.279.18.1458"},{"key":"CR8","volume-title":"Perceptions of Health and Illness: Current Research and Applications","year":"1997","unstructured":"Petrie KJ, Weinman JA, eds. Perceptions of Health and Illness: Current Research and Applications. London: Harwood Academic Publishers, 1997."},{"key":"CR9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1037\/0278-6133.4.2.115","volume":"4","author":"D Meyer","year":"1995","unstructured":"Meyer D, Leventhal H, Gutmann M. Common-sense models of illness: The example of hypertension. Health Psychol 1995;4:115?135.","journal-title":"Health Psychol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0022-3999(99)00057-4","volume":"47","author":"R Horne","year":"1999","unstructured":"Horne R, Weinman J. Patients? beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555?567.","journal-title":"J Psychosom Res"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2710.2000.00315.x","volume":"25","author":"DN Kiortsis","year":"2000","unstructured":"Kiortsis DN, Giral P, Bruckert E, et al. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000;25:445? 451.","journal-title":"J Clin Pharm Ther"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","volume":"303","author":"Simon Broome Steering Committee","year":"1991","unstructured":"Simon Broome Steering Committee. Risk of fatal coronary disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893?896.","journal-title":"BMJ"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ajmg.a.30102","volume":"128","author":"TM Marteau","year":"2004","unstructured":"Marteau TM, Senior V, Humphries SE, et al. Psychological impact of genetic testing for Familial Hypercholesterolemia with a previously aware population: A randomized controlled trial. AJMG 2004:128:285?293.","journal-title":"AJMG"},{"key":"CR14","volume-title":"Cardiovascular Survey Methods","author":"GA Rose","year":"1982","unstructured":"Rose GA, Blackburn H, Gillum RF, et al. Cardiovascular Survey Methods, 2nd ed. Geneva: World Health Organisation, 1982.","edition":"2"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08870440290001494","volume":"17","author":"R Moss Morris","year":"2002","unstructured":"Moss Morris R, Weinman J, Petrie KJ, et al. The Revised Illness Perception Questionnaire (IPQ-R). Psychology and Health 2002;17:1?16.","journal-title":"Psychology and Health"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.2044-8260.1992.tb00997.x","volume":"31","author":"TM Marteau","year":"1992","unstructured":"Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992;31:301?306.","journal-title":"Br J Clin Psychol"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 1983:67;361? 370.","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"CR18","first-page":"185","volume-title":"Developmental Aspects of Health Compliance Behavior","author":"P. Rudd","year":"1993","unstructured":"Rudd P. The measurement of compliance: medication taking. In: Krasnegor NA, Epstein LH, Johnson SB, et al, eds. Developmental Aspects of Health Compliance Behavior. Hillsdale, New Jersey: Lawrence Erlbaum 1993:185? 213."},{"key":"CR19","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1001\/archinte.160.14.2101","volume":"160","author":"MR DiMatteo","year":"2000","unstructured":"DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101?2107.","journal-title":"Arch Intern Med"},{"key":"CR20","unstructured":"Sheeran P. Intention-behaviour relations: A conceptual and empirical review. In Hewstone M, Stroebe W, eds. European Review of Social Psychology (in press);11."},{"key":"CR21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/(SICI)1099-0992(199903\/05)29:2\/3<349::AID-EJSP931>3.0.CO;2-Y","volume":"29","author":"P Sheeran","year":"1999","unstructured":"Sheeran P, Orbell S. Implementation intentions and repeated behaviour: Augmenting the predictive validity of the theory of planned behaviour. European Journal of Social Psychology 1999;29:349?369.","journal-title":"European Journal of Social Psychology"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-004-6225-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-004-6225-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-004-6225-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T13:27:53Z","timestamp":1559222873000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-004-6225-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["6225"],"URL":"https:\/\/doi.org\/10.1007\/s10557-004-6225-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}